Related Experiment Video
Updated: Mar 24, 2026
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory
Patrizia Vici1, Simonetta Buglioni2, Domenico Sergi1
1Division of Medical Oncology B, "Regina Elena" National Cancer Institute, Rome, Italy.
Abstract:
Cervical cancer cells commonly harbour a defective G1/S checkpoint owing to the interaction of viral oncoproteins with p53 and retinoblastoma protein. The activation of the G2/M checkpoint may thus become essential for protecting cancer cells from genotoxic insults, such as chemotherapy. In 52 cervical cancer patients treated with neoadjuvant chemotherapy, we investigated whether the levels of phosphorylated Wee1 (pWee1), a key G2/M checkpoint kinase, and γ-H2AX, a marker of DNA double-strand breaks, discriminated between patients with a pathological complete response (pCR) and those with residual disease. We also tested the association between pWee1 and phosphorylated Chk1 (pChk1), a kinase acting upstream Wee1 in the G2/M checkpoint pathway. pWee1, γ-H2AX and pChk1 were retrospectively assessed in diagnostic biopsies by immunohistochemistry. The degrees of pWee1 and pChk1 expression were defined using three different classification methods, i.e., staining intensity, Allred score, and a multiplicative score. γ-H2AX was analyzed both as continuous and categorical variable. Irrespective of the classification used, elevated levels of pWee1 and γ-H2AX were significantly associated with a lower rate of pCR. In univariate and multivariate analyses, pWee1 and γ-H2AX were both associated with reduced pCR. Internal validation conducted through a re-sampling without replacement procedure confirmed the robustness of the multivariate model. Finally, we found a significant association between pWee1 and pChk1. The message conveyed by the present analysis is that biomarkers of DNA damage and repair may predict the efficacy of neoadjuvant chemotherapy in cervical cancer. Further studies are warranted to prospectively validate these encouraging findings.
Insights
Biomarkers like phosphorylated Wee1 (pWee1) and γ-H2AX indicate DNA damage and may predict cervical cancer chemotherapy response. Elevated levels are linked to lower pathological complete response (pCR) rates, suggesting their potential in treatment efficacy prediction.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cervical cancer often has a faulty G1/S checkpoint due to viral oncoproteins.
- The G2/M checkpoint is crucial for cancer cell survival against genotoxic chemotherapy.
- Understanding checkpoint activation is key to improving treatment outcomes.
Purpose of the Study:
- To investigate if phosphorylated Wee1 (pWee1) and γ-H2AX levels predict pathological complete response (pCR) in cervical cancer patients.
- To assess the association between pWee1 and phosphorylated Chk1 (pChk1) in the G2/M checkpoint pathway.
- To determine if these biomarkers can discriminate between patients achieving pCR and those with residual disease after neoadjuvant chemotherapy.
Main Methods:
- Retrospective analysis of diagnostic biopsies from 52 cervical cancer patients treated with neoadjuvant chemotherapy.
- Immunohistochemistry was used to assess pWee1, γ-H2AX, and pChk1 expression.
- Statistical analyses, including univariate and multivariate models with internal validation, were performed to evaluate biomarker associations with pCR.
Main Results:
- Elevated levels of pWee1 and γ-H2AX were significantly associated with a lower rate of pCR, irrespective of the classification method used.
- Both pWee1 and γ-H2AX were independently associated with reduced pCR in univariate and multivariate analyses.
- A significant association was found between pWee1 and pChk1, supporting their role in the G2/M checkpoint pathway.
Conclusions:
- Biomarkers of DNA damage and repair, specifically pWee1 and γ-H2AX, show potential in predicting neoadjuvant chemotherapy efficacy in cervical cancer.
- These findings suggest that checkpoint activation markers could guide treatment strategies.
- Prospective validation studies are needed to confirm these predictive capabilities.
